Please login to the form below

Not currently logged in
Email:
Password:

opioids

This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.

FDA clears Sandoz and Pear’s Opioid Use Disorder app

FDA clears Sandoz and Pear’s Opioid Use Disorder app

High levels of patients relapsing into opioid dependency is a major part of the problem, particularly in the US, which has reached crisis levels in the country in recent years. ... Corey McCann, President and CEO of Pear Therapeutics, said: “Nearly 50,

Latest news

More from news
Approximately 15 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    These companies have been running out of cash and have had to do deals to stay alive.  Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    It has the potential to reduce pain without typical opioid therapy side effects and is in development for topical application in hypersensitivity disorders such as Bladder Pain Syndrome or Chronic Stump

  • How digital content helps HCPs curb opioid abuse through better prescribing decisions How digital content helps HCPs curb opioid abuse through better prescribing decisions

    In fact, a poll of physicians within our digital community found that 64% believe that doctors have a responsibility to help curb opioid abuse. ... And by delivering information concisely and in an engaging format, this approach is having a measurable

  • Deal Watch March 2016 Deal Watch March 2016

    $110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.

  • Pharma deals in September 2015 Pharma deals in September 2015

    Zalviso is a combination drug and device product which uses a patient controlled dispenser to deliver a sub-lingual formulation of sufentanil, an opioid with a high therapeutic index.

More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics